FutureChem Applies for Clinical Trial Plan of Prostate Cancer Targeted Therapy 'FC705' Phase 1

[Asia Economy Reporter Minji Lee] FutureChem, a company specializing in the development of new radiopharmaceutical drugs, announced on the 23rd that it has submitted an IND (Investigational New Drug application) for the Phase 1 clinical trial of FC705, a PSMA-based prostate cancer treatment, to the Ministry of Food and Drug Safety.

The clinical trial will be conducted at Seoul St. Mary's Hospital. Linical Korea, the Korean branch of the global CRO (Contract Research Organization) Linical Accelovance, will be in charge of the trial. The goal is to administer the first patient within the second half of the year.

FC705 is a new drug created by conjugating a therapeutic radioactive isotope (Lu-177) to a compound that selectively targets PSMA (Prostate-Specific Membrane Antigen), a receptor highly expressed in prostate cancer cells. The radiation emitted from the drug irradiates normal cells minimally while delivering a high dose to metastatic prostate cancer sites, allowing treatment of prostate cancer through several injections without surgical intervention.

Preclinical studies conducted at the Korea Institute of Radiological & Medical Sciences showed that FC705 has a higher cancer cell uptake rate and lower normal cell uptake rate compared to the competing compound PSMA617 from the U.S. company Endocyte, suggesting fewer side effects and higher therapeutic efficacy.

A FutureChem representative stated, “We plan to conduct a global Phase 1 clinical trial simultaneously with the domestic Phase 1 trial. We signed a contract with Linical Accelovance in February for domestic and international clinical trials, and within this year, we will begin preparations for the global Phase 1 trial to establish a foundation for entry into the U.S. and European markets.”

This content was produced with the assistance of AI translation services.